PMID- 14716700
OWN - NLM
STAT- MEDLINE
DCOM- 20040401
LR  - 20220409
IS  - 0885-6230 (Print)
IS  - 0885-6230 (Linking)
VI  - 19
IP  - 1
DP  - 2004 Jan
TI  - A multinational, randomised, 12-week study comparing the effects of donepezil and 
      galantamine in patients with mild to moderate Alzheimer's disease.
PG  - 58-67
AB  - OBJECTIVES: To compare directly, in the same patient cohort, the ease of use and 
      tolerability of donepezil and galantamine in the treatment of Alzheimer's disease 
      (AD), and investigate the effects of both treatments on cognition and activities 
      of daily living (ADL). METHODS: Patients with mild to moderate AD from 14 
      European centres were randomised to receive open-label donepezil (up to 10 mg 
      once daily) or galantamine (up to 12 mg twice daily) for 12 weeks, according to 
      the approved product labelling. Physicians and caregivers completed 
      questionnaires rating satisfaction with treatment/ease of use in daily practice. 
      Secondary assessments were the ADAS-cog, the MMSE, and the DAD scale to assess 
      ADL. Tolerability was evaluated by reporting adverse events (AEs). RESULTS: Both 
      physicians and caregivers reported significantly greater overall 
      satisfaction/ease of use for donepezil (n = 64) compared with galantamine (n = 
      56) at weeks 4, 12, and endpoint (week 12 LOCF; all p-values <0.05). 
      Significantly greater improvements in cognition were also observed for donepezil 
      versus galantamine on the ADAS-cog at Week 12 and endpoint (p-values <0.05). ADL 
      improved significantly in the donepezil group compared with the galantamine group 
      at weeks 4, 12, and endpoint (p-values <0.05). Most AEs were mild to moderate, 
      however, 46% galantamine-treated patients reported gastrointestinal AEs vs 25% 
      donepezil patients. CONCLUSIONS: Physician and caregiver ease of use/satisfaction 
      scores, and assessments of cognition and ADL, showed significant benefits for 
      donepezil compared with galantamine in this direct comparative trial. Both 
      treatments were well tolerated, with more gastrointestinal AEs reported for 
      galantamine vs donepezil.
CI  - Copyright 2004 John Wiley & Sons, Ltd.
FAU - Jones, Roy W
AU  - Jones RW
AD  - Research Institute for the Care of the Elderly, St Martin's Hospital, Bath, UK. 
      r.w.jones@bath.ac.uk
FAU - Soininen, Hilkka
AU  - Soininen H
FAU - Hager, Klaus
AU  - Hager K
FAU - Aarsland, Dag
AU  - Aarsland D
FAU - Passmore, Peter
AU  - Passmore P
FAU - Murthy, Anita
AU  - Murthy A
FAU - Zhang, Richard
AU  - Zhang R
FAU - Bahra, Ranbir
AU  - Bahra R
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Int J Geriatr Psychiatry
JT  - International journal of geriatric psychiatry
JID - 8710629
RN  - 0 (Cholinesterase Inhibitors)
RN  - 0 (Indans)
RN  - 0 (Nootropic Agents)
RN  - 0 (Piperidines)
RN  - 0D3Q044KCA (Galantamine)
RN  - 8SSC91326P (Donepezil)
SB  - IM
CIN - Evid Based Ment Health. 2004 Aug;7(3):77. PMID: 15273221
CIN - Int J Geriatr Psychiatry. 2005 Jan;20(1):85-7; author reply 87-9. PMID: 15635772
MH  - Activities of Daily Living
MH  - Aged
MH  - Aged, 80 and over
MH  - Alzheimer Disease/*drug therapy/psychology
MH  - Attitude of Health Personnel
MH  - Attitude to Health
MH  - Caregivers/psychology
MH  - Cholinesterase Inhibitors/*therapeutic use
MH  - Cognition/drug effects
MH  - Donepezil
MH  - Female
MH  - Galantamine/*therapeutic use
MH  - Humans
MH  - Indans/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Nootropic Agents/therapeutic use
MH  - Piperidines/*therapeutic use
MH  - Treatment Outcome
EDAT- 2004/01/13 05:00
MHDA- 2004/04/02 05:00
CRDT- 2004/01/13 05:00
PHST- 2004/01/13 05:00 [pubmed]
PHST- 2004/04/02 05:00 [medline]
PHST- 2004/01/13 05:00 [entrez]
AID - 10.1002/gps.1038 [doi]
PST - ppublish
SO  - Int J Geriatr Psychiatry. 2004 Jan;19(1):58-67. doi: 10.1002/gps.1038.